Iris Schrader
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jückstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers (Basel) 2022; 14
Mar 28, 2022MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Mar 28, 2022Cancers (Basel) 2022; 14
Huebner Hanna, Tesch Hans, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Rezai Mahdi, Beckmann Matthias W, Fasching Peter A, Janni Wolfgang, Schneeweiss Andreas, Nabieva Naiba, Jückstock Julia, Häberle Lothar, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Schochter Fabienne, Bekes Inga, Mahner Sven, Rack Brigitte
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res 2020; 22:111.
Oct 23, 2020Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
Oct 23, 2020Breast Cancer Res 2020; 22:111
De Gregorio Amelie, Schneeweiss Andreas, Tesch Hans, Mahner Sven, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Lato Krisztian, Beckmann Matthias W, Rack Brigitte, Andergassen Ulrich, Bekes Inga, Fink Visnja, Häberle Lothar, Fasching Peter A, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Friedl Thomas W P, Bauer Emanuel, De Gregorio Nikolaus, Deniz Miriam, Janni Wolfgang
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Karn T, Schem C, Young B, Hanusch C, Stickeler E, Huober J, van Mackelenbergh M, Leyland-Jones B, Fehm T, Nekljudova V, Untch M, Gerber B, Holtrich U, Müller V, Meissner T, Weber K, Solbach C, Denkert C, Engels K, Fasching P, Sinn B, Schrader I, Budczies J, Marme F, Loibl S. A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res 2020; 26:1896-1904.
Jan 13, 2020A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Jan 13, 2020Clin Cancer Res 2020; 26:1896-1904
Karn Thomas, Schem Christian, Young Brandon M, Hanusch Claus, Stickeler Elmar, Huober Jens, van Mackelenbergh Marion, Leyland-Jones Brian, Fehm Tanja, Nekljudova Valentina, Untch Michael, Gerber Bernd, Holtrich Uwe, Müller Volkmar, Meissner Tobias, Weber Karsten E, Solbach Christine, Denkert Carsten, Engels Knut, Fasching Peter A, Sinn Bruno V, Schrader Iris, Budczies Jan, Marme Frederik, Loibl Sibylle
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
Deniz M, Andergassen U, Steidl J, Trapp E, Fasching P, Häberle L, Beckmann M, Schneeweiss A, Schrader I, Janni W, Rack B, Jueckstock J, Kost B, deGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer E, Aivazova-Fuchs V, Weissenbacher T, Friedl T. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. Breast 2018; 44:81-89.
Dec 20, 2018Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
Dec 20, 2018Breast 2018; 44:81-89
Deniz Miriam, Andergassen Ullrich, Steidl Julia, Trapp Elisabeth, Fasching Peter A, Häberle Lothar, Beckmann Matthias W, Schneeweiss Andreas, Schrader Iris, Janni Wolfgang, Rack Brigitte, Jueckstock Julia, Kost Bernd, deGregorio Amelie, DeGregorio Nikolaus, Bekes Inga, Widschwendter Peter, Schochter Fabienne, Ernst Kristina, Scholz Christoph, Bauer Emanuel Ca, Aivazova-Fuchs Viktoria, Weissenbacher Tobias, Friedl Thomas Wp
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Riethdorf S, Untch M, von Minckwitz G, Schem C, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Weber K, Nekljudova V, Loibl S, Müller V, Pantel K. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res 2017; 23:5384-5393.
Jul 5, 2017Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial
Jul 5, 2017Clin Cancer Res 2017; 23:5384-5393
Riethdorf Sabine, Untch Michael, von Minckwitz Gunter, Schem Christian, Tesch Hans, Holms Frank, Hilfrich Jörn, Schrader Iris, Fehm Tanja, Huober Jens, Weber Karsten, Nekljudova Valentina, Loibl Sibylle, Müller Volkmar, Pantel Klaus
Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
Gerber B, Loibl S, Nekljudova V, Hauschild M, Huober J, Blohmer J, Kunz G, Jackisch C, Solbach C, Hanusch C, Kittel K, Schrader I, Eggemann H, Tesch H, Fasching P, Rezai M, Eidtmann H, von Minckwitz G, Untch M. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol 2014; 21:2517-24.
Apr 18, 2014Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44)
Apr 18, 2014Ann Surg Oncol 2014; 21:2517-24
Gerber Bernd, Loibl Sibylle, Nekljudova Valentina, Hauschild Maik, Huober Jens, Blohmer Jens-Uwe, Kunz Georg, Jackisch Christian, Solbach Christine, Hanusch Claus, Kittel Kornelia, Schrader Iris, Eggemann Holm, Tesch Hans, Fasching Peter, Rezai Mahdi, Eidtmann Holger, von Minckwitz Gunter, Untch Michael
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Lück H, Schuster T, Wollschläger K, Untch M, Thomssen C, Eidtmann H, Stickeler E, Richter B, Hubalek M, Jackisch C, Stähler A, Beckmann M, Heilmann V, Huober J, Schrader I, Loibl S, du Bois A, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 2013; 139:779-87.
Jun 15, 2013Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Jun 15, 2013Breast Cancer Res Treat 2013; 139:779-87
Lück Hans-Joachim, Schuster Tibor, Wollschläger Kerstin, Untch Michael, Thomssen Christoph, Eidtmann Holger, Stickeler Elmar, Richter Barbara, Hubalek Michael, Jackisch Christian, Stähler Ann, Beckmann Matthias, Heilmann Volker, Huober Jens, Schrader Iris, Loibl Sibylle, du Bois Andreas, von Minckwitz Gunter
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
von Minckwitz G, Blohmer J, Huober J, Hauschild M, Fehm T, Müller B, Denkert C, Loibl S, Nekljudova V, Untch M, German Breast Group, Kunz G, Jackisch C, Gerber B, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366:299-309.
Jan 26, 2012Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
Jan 26, 2012N Engl J Med 2012; 366:299-309
von Minckwitz Gunter, Blohmer Jens-Uwe, Huober Jens, Hauschild Maik, Fehm Tanja, Müller Berit Maria, Denkert Carsten, Loibl Sibylle, Nekljudova Valentina, Untch Michael, German Breast Group, Kunz Georg, Jackisch Christian, Gerber Bernd, Eidtmann Holger, Rezai Mahdi, Fasching Peter A, Tesch Hans, Eggemann Holm, Schrader Iris, Kittel Kornelia, Hanusch Claus, Kreienberg Rolf, Solbach Christine, Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
von Minckwitz G, Untch M, Diebold K, Tiemann K, Hoffmann G, Henschen S, Schrader I, Hanusch C, Clemens M, Just M, Dietrich K, Eidtmann H, Holms F, Solbach C, Tesch H, Huober J, Loibl S, Darb-Esfahani S, Denkert C. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2011
Jun 12, 2011Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
Jun 12, 2011Breast Cancer Res Treat 2011
von Minckwitz Gunter, Untch Michael, Diebold Kurt, Tiemann Katharina, Hoffmann Gerald, Henschen Stephan, Schrader Iris, Hanusch Claus, Clemens Michael R, Just Marianne, Dietrich Klaus, Eidtmann Holger, Holms Frank, Solbach Christine, Tesch Hans, Huober Jens, Loibl Sibylle, Darb-Esfahani Silvia, Denkert Carsten
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Riethdorf S, von Minckwitz G, Untch M, Eidtmann H, Tesch H, Holms F, Hilfrich J, Schrader I, Fehm T, Huober J, Roller M, Komor M, Loibl S, Rau T, Zhang L, Müller V, Pantel K. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16:2634-45.
Apr 20, 2010Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial
Apr 20, 2010Clin Cancer Res 2010; 16:2634-45
Riethdorf Sabine, von Minckwitz Gunter, Untch Michael, Eidtmann Holger, Tesch Hans, Holms Frank, Hilfrich Jörn, Schrader Iris, Fehm Tanja, Huober Jens, Roller Marc, Komor Martina, Loibl Sibylle, Rau Thomas, Zhang Liling, Müller Volkmar, Pantel Klaus